Robert F. Kennedy, Jr. is one of the attorneys in the Jennifer Robi vs. Merck and Kaiser Permanente fraud case currently being litigated in Los Angeles Superior Court. This must-watch video, referencing much of the science presented as evidence during the trial, details the many problems with the development and safety of Merck’s third-highest grossing product, Gardasil. Children’s Health Defense (CHD) and Robert F. Kennedy, Jr., CHD’s Chairman and Chief Legal Counsel, ask that you watch and share this video so that you, and others, may make an informed decision of whether or not to give your child, boy or girl, a Gardasil vaccine. It can also be a useful tool for pediatricians who are trying to understand how this vaccine, that is actually causing health problems with young people, could have been approved by FDA and then recommended by CDC. The video is full of jaw-dropping facts about Gardasil and the clinical trials leading up to its release upon an unsuspecting public.
There is nothing like a good "measles outbreak" to boost sales when you have a monopoly on the only measles vaccine available, and corporate-funded mainstream media does almost all of your marketing for free, by singing the praises of the vaccine while never mentioning potential side effects or criminal cases currently in place over corruption surrounding the development of the vaccine. Given the fact that U.S. law prevents anyone from suing Merck if a vaccine injury or death occurs from their vaccines, and that the U.S. Government via the CDC is the largest purchaser of vaccines to the tune of $5 billion per year, the vaccine industry has become perhaps the most lucrative market in the history of the world. Merck & Co Inc. reported higher-than-expected first-quarter profits for 2019. Sales of the MMR measles vaccine soared to 27% to $496 million. The company also saw strong sales growth overseas for its Gardasil vaccine, as sales rose 27 percent to $828 million, beating analyst expectations by about $25 million.
It was truly a red-letter day. Jennifer’s lawyers brilliantly laid bare Merck’s anemic case for Gardasil, dissecting the science in withering presentations challenging both the efficacy and safety of the Gardasil vaccine, and then chronicling the horrifying agency and corporate corruption that lead to its approval. Jennifer Robi is a 24-year-old former athlete and scholar who has been confined to a wheelchair since receiving her third Gardasil vaccines at age sixteen. She suffers continual uncontrolled neuro/muscular contractions (jerking) and postural orthostatic tachycardia syndrome (POTS) and many other symptoms of systemic autoimmune dysregulation. Jennifer’s attorney, Sol Ajalat, initially brought her case in Vaccine Injury Compensation Program and then, following a judgment in the program, elected to proceed in civil court. Since VICA (the Vaccine Injury Compensation Act) forbids recoveries for product defect or negligence, Ajalat brought Jennifer’s civil case under the theories that Merck committed fraud during its clinical trials and then failed to warn Jennifer (and, by implication, other injured girls) about the high risks and meager benefits of the vaccine. In order to support Sol Ajalat and his sons Greg, Larry, and Steve, who compose the Los Angeles firm Ajalat & Ajalat, a blue ribbon A-Team of the nation’s leading plaintiffs’ law firms have joined Jennifer’s trial team. These include the firms most feared by Pharma: Weitz & Luxenberg (countless major pieces of litigation over 30 years), Morgan & Morgan (Vioxx, Phenphen, Breast Implants, Tobacco), Baum Hedlund, (Monsanto $289 million verdict 2018 and the $54 million 2000 verdict against Bayer in Haemophiliac/AIDS case) as well as Children’s Health Defense’s own Robert F. Kennedy, Jr. and Kim Mack Rosenberg (a co-author of The HPV on Trial).
In the summer of 2017, a malware virus mainly affecting the Ukraine, found its way onto the mainframe computer systems of Merck wreaking havoc for the company. According to the Wall Street Journal, the incident cost the pharmaceutical giant $670 million to remediate, but more importantly, it caused disruption to the production of two of Merck’s pediatric vaccines: Gardasil 9 (Human Papillomavirus) and Recombivax (Hepatitis B virus), vaccines to help prevent sexually transmitted infections. During the crisis, Merck borrowed from a CDC vaccine stockpile, in order to meet supply commitments for Gardasil 9. However, that was not the case with Recombivax, the Hepatitis B vaccine given to all babies beginning the first day of life. There is growing concern among some scientists about the aluminum adjuvant load in vaccines and its effects on the neurological health of children. Researchers are particularly concerned with Merck’s highly immunogenic adjuvant, Amorphous Aluminum Hydroxyphosphate Sulphate (AAHS). Gardasil and Recombivax are the only vaccines licensed to contain AAHS. We now have more than a year’s worth of data to examine since the attack in 2017 when Engerix-B was introduced. On average there were 29 deaths reported annually for fifteen years prior to the attack (2003 to 2017). In 2018 there were only 6 reported (to end of November 2018). Two of those deaths followed Recombivax.
Merck's Gardasil vaccine saw a 55% increase over last year’s third quarter, netting $1.05 billion in global sales for the third quarter of 2018. Thanks to worldwide sales, the Gardasil vaccine has become the top money maker for Merck. FiercePharma, the marketing trade publication for vaccine manufacturers, reports that Merck’s Gardasil has been propelling the pharma giant’s vaccine unit in recent quarters, and that doesn't look like it'll be changing. The company sees more growth ahead thanks to an “unprecedented increase in worldwide demand” for HPV vaccines, an executive said. Addressing the vaccine's performance on a recent conference call, Merck’s president of global human health Adam Schechter said the company is “seeing unprecedented increase in worldwide demand for the HPV vaccines.” He said global demand has “doubled in the last year alone.” Meanwhile, the carnage left behind from mass Gardasil vaccination programs continues to get world-wide exposure, as doctors, scientists, and victims look for ways to oppose mass Gardasil vaccination programs. A recent gathering in Ireland at an IFICA conference brought together many world leaders to discuss the Gardasil problem, and another meeting is scheduled in the U.S. in 2019 during the Autism One conference, at the 4th Annual International HPV Vaccine Education Symposium.
The lawfirm of Maglio Christopher & Toale, P.A. announced earlier this month (July, 2018) that they had negotiated a $101 million dollar settlement for an infant who suffered a severe reaction to the Measles Mumps Rubella (MMR) vaccine. A one-year-old healthy baby girl, who was already walking and climbing, received vaccinations for Measles Mumps Rubella (MMR), Hepatitis A, Haemophilus Influenzae type B (Hib), Prevnar (pneumonia), and Varicella (chickenpox) on February 13, 2013. That evening, the mother noticed the baby was irritable and feverish. After a call to the pediatrician, the doctor advised Mom to give her Tylenol and Benadryl. The fever continued for several days, and on the evening before the baby’s scheduled pediatrician visit, the baby began having severe seizures. She was rushed to the emergency room. She went into cardiac and respiratory arrest, and doctors placed her on a ventilator. The seizures and cardiac arrest left the baby with a severe brain injury, encephalopathy, cortical vision impairment, truncal hypotonia (low muscle tone), and kidney failure. After months of treatment at the hospital, the baby finally went home, but her disabilities required specialized medical care and supervision around the clock for the rest of her life. The $101 million dollar settlement will pay for the child’s constant high-level medical care for the rest of her life. The family received a lump sum of $1 million dollars to cover the immediate costs of medical bills and expenses. The rest will be paid out through an annuity over the child’s lifetime. Don't expect to read this story in the Big Pharma-sponsored corporate "mainstream" media, where the official doctrine is that vaccines are "safe and effective."
Merck Receives FDA Priority Review to Expand Dangerous Gardasil Vaccine to Women and Men Ages 27 to 45
Gardasil vaccine manufacturer, Merck, announced earlier this month (June, 2018) that the U.S. Food and Drug Administration (FDA) has granted them a "Priority Review" to approve the dangerous and controversial Gardasil 9 vaccine to women and men, ages 27 to 45. The Gardasil vaccine is currently approved for girls and boys, ages 9 through 26. The request by Merck to expand its market to women and men, ages 27 to 45, and the FDA's approval to grant it a Priority Review by October 6, 2018, follows 10 years after the FDA struck down a similar request to expand the older version of Gardasil to the same age group. Besides the hundreds of stories of young women being injured or even killed by the Gardasil vaccine, as well as the lawsuits mounting in countries outside the U.S., the published data regarding Gardasil just keeps getting worse. Will the FDA consider these studies in determining if Gardasil should be expanded to a larger population? Shouldn't the FDA instead be determining if Gardasil should even stay in the market, as other countries are beginning to ask?
Last month (May, 2018) we published a report from the vaccine marketing trade publication, Fierce Pharma, that Merck's sales this year were beating financial forecasts, primarily due to its entrance into the China market for its top-selling Gardasil HPV vaccine. Fierce Pharma reported at that time that the Gardasil vaccine was fast-tracked for approval into the China market: "Late last month, the Chinese FDA granted Gardasil 9 a conditional approval only nine days into a review." Now, Fierce Pharma is reporting that Gardasil's acceptance into the China market has produced instant billionaires.
Merck’s Fosamax Fraud Demonstrates How Big Pharma and CDC Spin Statistics to Sell Ineffective Vaccines and Drugs
It has been over a decade since I came to the realization that the entire profession of medicine had been bamboozled by the propaganda coming from the Big Pharma drug and vaccine maker, Merck & Company, that its so-called “fracture-preventative” drug Fosamax had defrauded us doctors and our patients by falsely claiming a “50% efficacy rate” in the prevention of bone fractures in osteopenic/osteoporotic women. By doing a little math, I understood that the honest truth of the matter was that patients who took the drug for four years had a miniscule 1-2% absolute risk reduction (AAR) in the incidence of fractures, which is a much more realistic figure that Merck, being a sociopathic entity that is inclined to tell half-truths or outright lies, chose not to use in its advertisements. It is a fact that being truthful in the drug or vaccine industry is an impediment to selling product, because they would be admitting they were selling a lousy, fraudulent, relatively ineffective or dangerous drug or vaccine. In other words, Big Pharma/BigVaccine is still successfully bamboozling us doctors and patients (as well as Big Media, the CDC, the FDA, the AMA, the AAP, the APA, the AAFP, the NIH, the NIMH, Wall Street and our politicians) with the old deceptive tactic of using relative risk reduction statistics about vaccine efficacy rather than honestly telling us the more truthful absolute risk reduction figures whenever they are rolling out their newest – and increasingly unaffordable – vaccines. Therefore, I devote the remainder of this column to reporting some excerpts from the internet and end with some examples of published studies from courageous researchers who have gone up against the drug industry and reported the important statistics that we should all demand to know when a vaccine (or drug) is being sold to us.
The pharmaceutical marketing trade publication, Fierce Pharma, announced this month (May 2018) that Merck has beat Wall Street expectations for their Gardasil vaccine sales during the first quarter of 2018, achieving 24% growth with $660 million for the HPV vaccine. The report notes that sales in the U.S. are declining, attributing the decline in sales to the CDC decision to reduce their recommendation of the Gardasil vaccine to be only two doses, instead of three. Nothing is mentioned about declining public opinion regarding Gardasil, nor the numerous lawsuits against the company outside the U.S. The increase in sales for Gardasil is attributed to their entrance into the China market. The original vaccine won Chinese approval last year, while late last month the Chinese FDA granted Gardasil 9 a conditional approval only nine days into a review.